A novel genus of virulent phage targeting Acinetobacter baumannii: Efficacy and safety in a murine model of pulmonary infection
PLOS Pathogens · 2025
DOI: 10.1371/journal.ppat.1013268 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2025. Verfasst von JiaWang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Phage Therapy, Bacteriophages. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fujian Provincial Department of Science and Technology, Ministry of Science and Technology of the People's Republic of China, Fujian Provincial Major Health Research Project.
Abstract (Originalsprache)
Acinetobacter baumannii is a notable opportunistic pathogen responsible for severe hospital-acquired infections, with multidrug-resistant strains posing significant treatment challenges. Phage therapy, which employs bacteriophages as natural bacterial antagonists, has gained renewed attention as a promising solution to combat antibiotic-resistant infections. In this study, we isolated and characterized a novel virulent phage, vB_AbaS_qsb1, which specifically lyses A.baumannii . Phylogenetic and genomic analyses indicate that vB_AbaS_qsb1 is the founding member of a previously unreported genus, which we propose to name Acinibactriovirus , with Acinibactriovirus lysinus as the type species. vB_AbaS_qsb1 demonstrated robust stability across diverse temperature and pH ranges, a short latent period, and no known virulence or antibiotic resistance genes within its 54,713 bp dsDNA genome. Safety assessments showed that high-dose vB_AbaS_qsb1 induced no adverse effects in mice, with histopathology confirming its safety profile. Therapeutic experiments further indicated that vB_AbaS_qsb1 provided at least 50% protection against A.baumannii -induced pneumonia, significantly reducing bacterial loads and inflammation markers, while maintaining high phage titers in lung tissue.This study introduces vB_AbaS_qsb1 as a promising candidate for phage therapy against A.baumannii , offering both innovative insights and a valuable framework for future isolation, genomic characterization, and efficacy evaluation of phages targeting antibiotic-resistant bacteria.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Pharmacy, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
- Institute of Applied Genomics, Fuzhou University, Fuzhou, China.
- College of Biological Science and Engineering, Fuzhou University, Fuzhou, China.
ORCID-Profile: XiaoLing Yu
Förderung
- Fujian Provincial Department of Science and Technology
- Ministry of Science and Technology of the People's Republic of China
- Fujian Provincial Major Health Research Project
- Fuzhou Municipal Health Commission
- National Key Research & Development Plan
- Fuzhou University
Zitieren
APA
Wang, J., Hu, H., Wang, Q., Zhu, T., Ren, X., Jiang, W., Hou, X., Lin, J., & Yu, X. (2025). A novel genus of virulent phage targeting Acinetobacter baumannii: Efficacy and safety in a murine model of pulmonary infection. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013268
Vancouver
Wang J, Hu H, Wang Q, Zhu T, Ren X, Jiang W, et al. A novel genus of virulent phage targeting Acinetobacter baumannii: Efficacy and safety in a murine model of pulmonary infection. PLOS Pathogens. 2025. doi:10.1371/journal.ppat.1013268
BibTeX
@article{Wang2025,
author = {Wang, JiaWang and Hu, Huan and Wang, QingQing and Zhu, TianZhu and Ren, XiaoHan and Jiang, WenQian and Hou, XueMei and Lin, Jun and Yu, XiaoLing},
title = {A novel genus of virulent phage targeting Acinetobacter baumannii: Efficacy and safety in a murine model of pulmonary infection},
journal = {PLOS Pathogens},
year = {2025},
doi = {10.1371/journal.ppat.1013268}
}
EUVIMED